What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) developed by Novo Nordisk in the mid-1990s. It belongs to the class of GH secretagogues that act at the ghrelin receptor (GHS-R1a), stimulating pulsatile GH release from the anterior pituitary. Ipamorelin is structurally derived from GHRP-1 but was modified to achieve high GH-releasing potency with improved receptor selectivity, specifically to eliminate the prolactin and cortisol co-secretion observed with earlier GHRPs.
Its amino acid sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH2) incorporates several non-natural amino acids that confer metabolic stability and receptor binding selectivity. This design philosophy of achieving GH selectivity by eliminating off-target endocrine effects has made ipamorelin a reference compound for researchers studying GH secretagogue pharmacology.
GH Selectivity: The Key Distinction
The characteristic that most distinguishes ipamorelin in the GHRP research literature is its selectivity for GH secretion over other anterior pituitary hormones. Earlier GHRPs, particularly GHRP-2 and GHRP-6, were found to stimulate not only GH release but also co-secretion of prolactin, ACTH, and cortisol at pharmacologically relevant doses. These hormonal side effects complicate research protocols and limit interpretability when studying the specific effects of GH axis stimulation.
The landmark characterization study by Raun et al. (1998) in the European Journal of Endocrinology established that ipamorelin, unlike GHRP-2 and GHRP-6, produced minimal prolactin and ACTH/cortisol responses at doses producing equivalent GH stimulation in both rat and swine models. This selectivity profile was confirmed across a dose range sufficient to produce maximal GH stimulation, establishing ipamorelin as the most selective GHRP characterized at that time.
GH Pulse Amplitude and Pulsatility
Like other GHRPs, ipamorelin stimulates GH secretion in a pulsatile pattern consistent with physiological GH release, as opposed to the constant supraphysiological GH levels associated with exogenous GH administration. Studies have characterized the kinetics of ipamorelin-induced GH pulses in rodent models: GH release peaks approximately 15–30 minutes post-administration and returns to baseline within 2–3 hours, with pulse amplitudes increasing dose-dependently up to a ceiling effect.
Researchers have used ipamorelin to study the additive effects of combining GHRP and GHRH pathway stimulation. Studies examining ipamorelin in combination with GHRH analogues (such as CJC-1295) have reported synergistic GH pulse amplification, a finding consistent with the different but complementary mechanisms of the two receptor classes, with GHRP receptor activation amplifying GHRH-stimulated GH release through both direct pituitary effects and hypothalamic somatostatin suppression.
Body Composition Research
Preclinical studies in rodent models have examined ipamorelin's effects on body composition. Research in aged rats demonstrated dose-dependent increases in lean body mass and reductions in fat mass following sustained ipamorelin administration, consistent with the anabolic and lipolytic effects of increased GH/IGF-1 axis activity. Bone mineral density studies in rodent models have also reported beneficial effects on bone mass, consistent with known GH effects on osteoblast activity and bone remodeling.
Gastrointestinal Research
Ipamorelin was originally developed by Novo Nordisk with interest in gastrointestinal applications, specifically the treatment of postoperative ileus. Research demonstrated that ipamorelin stimulates gastrointestinal motility through GHS-R1a receptors expressed throughout the GI tract, consistent with ghrelin's known role as a prokinetic gut hormone. Phase II clinical trials examined ipamorelin in postoperative GI dysfunction, though these programs were ultimately discontinued before regulatory submission.
Advantages Over GHRP-2 and GHRP-6 for Research Use
For researchers specifically studying GH axis biology, ipamorelin's selectivity offers several practical advantages compared to older GHRPs:
- Hormonal specificity: Minimal prolactin and cortisol elevation simplifies interpretation of experimental outcomes attributable to GH/IGF-1 axis changes.
- Clean dose-response: Dose-dependent GH stimulation without the plateau-and-desensitization profiles reported with GHRP-6 at high doses.
- Reduced hunger stimulation: GHRP-6 is associated with significant appetite stimulation via ghrelin pathway activation; ipamorelin appears to produce less pronounced appetite effects in preclinical models.
- Established comparator data: The Raun et al. (1998) head-to-head comparison provides well-characterized reference data for experimental design.
Current Research Status
Ipamorelin has not received FDA approval for any indication. Its use in human research remains limited, with most available data derived from preclinical models and the discontinued GI motility clinical program. The compound's well-characterized selectivity profile and established pharmacokinetic properties make it a standard reference compound in GH secretagogue research.
Selected References
- Raun K, et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5):552–561.
- Johansen PB, et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research, 9(2):106–113.
- Svensson J, et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology, 165(3):569–77.
- Venkova K, et al. (2009). Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. Journal of Pharmacology and Experimental Therapeutics, 329(3):1110–6.
- Bowers CY. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12):1316–1329.